Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...